What is SBH Sciences?
Operating at the intersection of discovery research and commercial biotechnology, SBH Sciences provides a robust suite of services including cell-based assays, biomarker analysis, and comprehensive drug discovery support. With a legacy spanning over 28 years, the organization has established itself as a critical partner for both emerging startups and established pharmaceutical entities. Their portfolio, which includes high-purity recombinant cytokines, monoclonal antibodies, and specialized enzymes, serves as a foundational element for modern laboratory workflows. By maintaining state-of-the-art technological infrastructure, SBH Sciences effectively bridges the gap between early-stage scientific inquiry and scalable industrial application, ensuring that researchers have access to the precise tools required for complex drug development cycles.
How much funding has SBH Sciences raised?
SBH Sciences has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in SBH Sciences
PPP
Public-Private Partnership
What's next for SBH Sciences?
With the successful acquisition of this late-stage financing, SBH Sciences is well-positioned to scale its core service divisions and enhance its proprietary research capabilities. The strategic deployment of this capital will likely focus on optimizing high-throughput screening processes and expanding the firm's biomarker service portfolio to meet the increasing demand for precision medicine. As the biotechnology sector continues to prioritize efficiency and data-driven outcomes, SBH Sciences is poised to leverage its long-standing industry expertise to capture additional market share. Future growth trajectories will likely involve the integration of advanced analytical platforms and the expansion of their global distribution network, further cementing their role as a cornerstone provider in the life sciences ecosystem.
See full SBH Sciences company page
